Individualized Treatment for Patients With Familial Hypercholesterolemia

키워드

참고문헌 (94)

1. Mabuchi H, "Half a century tales of familial hypercholesterolemia(FH)in Japan", J Atheroscler Thromb, 24, pp.189~207 (2017)
2. Soutar AK, "Mechanisms of disease : genetic causes of familial hypercholesterolemia", Nat Clin Pract Cardiovasc Med, 4, pp.214~225 (2007)
3. Nohara A, "Homozygous familial hypercholesterolemia", J Atheroscler Thromb, 28, pp.665~678 (2021)
4. Foody JM, "Familial hypercholesterolemia", autosomal dominant hypercholesterolemia : Molecular defects, the LDL-C continuum, and gradients of phenotypic severity, 2016, pp.10, 970~986
5. Santos RD, "Phenotype vs. genotype in severe familial hypercholesterolemia : what matters most for the clinician?", Curr Opin Lipidol, 28, pp.130~135 (2017)
6. Bourbon M, "Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia : the SAFEHEART registry", Atherosclerosis, 262, pp.8~13 (2017)
7. Di Taranto MD, "Familial hypercholesterolemia : a complex genetic disease with variable phenotypes", Eur J Med Genet, 63, pp.103831~ (2020)
8. Gagné C, "Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia", Circulation, 105, pp.2469~2475 (2002)
9. Yamamoto A, "The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy", Atherosclerosis, 186, pp.126~131 (2006)
10. Gotto AM Jr, "Pharmacotherapies for lipid modification : beyond the statins", Nat Rev Cardiol, 10, pp.560~570 (2013)
11. Santos RD, "Long-term evolocumab in patients with familial hypercholesterolemia", J Am Coll Cardiol, 75, pp.565~574 (2020)
12. Harada-Shiba M, "Efficacy and safety of lomitapide in Japanese patients with homozygous familial hypercholesterolemia", J Atheroscler Thromb, 24, pp.402~411 (2017)
13. Nohara A, "Safety and efficacy of lomitapide in Japanese patients with homozygous familial hypercholesterolemia(HoFH) : results from the AEGR-733-301 long-term extension study", J Atheroscler Thromb, 26, pp.368~377 (2019)
14. Rosenson RS, "Evinacumab in patients with refractory hypercholesterolemia", N Engl J Med, 383, pp.2307~2319 (2020)
15. Agarwala A, "Bempedoic acid for heterozygous familial hypercholesterolemia : from bench to bedside", Drug Des Devel Ther, 15, pp.1955~1963 (2021)
16. Tada H, "Challenges of precision medicine for atherosclerotic cardiovascular disease based on human genome information", J Atheroscler Thromb, 28, pp.305~313 (2021)
17. Fagge CH, "Xanthomatous disease of the skin. I. General xanthelasma of vitiligoides", Trans Pathol Soc Lond, 24, pp.242~250 (1873)
18. Thannhauser SJ, "The different clinical groups of xanthomatous diseases : a clinical physiological study of 22 cases", Ann Intern Med, 11, pp.1162~ (1938)
19. Hori M, "The first Japanese cases of familial hypercholesterolemia due to a known pathogenic APOB gene variant, c. 10580 G>A : p. (Arg3527Gln)", J Clin Lipidol, 14, pp.482~486 (2020)
20. Harada-Shiba M, "Clinical features and genetic analysis of autosomal recessive hypercholesterolemia", J Clin Endocrinol Metab, 88, pp.2541~2547 (2003)
21. Tada H, "Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia : results from stable isotope kinetic study in vivo", Circ Cardiovasc Genet, 5, pp.35~41 (2012)
22. Abifadel M, "Mutations in PCSK9 cause autosomal dominant hypercholesterolemia", Nat Genet, 34, pp.154~156 (2003)
23. Goldstein JL, "The metabolic and molecular bases of inherited disease", pp.2863~2913 (2001), McGraw-Hill
24. Mabuchi H, "Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan", Atherosclerosis, 214, pp.404~407 (2011)
25. Benn M, "Mutations causative of familial hypercholesterolaemia : screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217", Eur Heart J, 37, pp.1384~1394 (2016)
26. de Ferranti SD, "Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States national health and nutrition examination surveys(NHANES)", Circulation, 133, pp.1067~1072 (2016)
27. Beheshti SO, "Worldwide prevalence of familial hypercholesterolemia : meta-analyses of 11 million subjects", J Am Coll Cardiol, 75, pp.2553~2566 (2020)
28. Hu P, "Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease : a systematic review and meta-analysis", Circulation, 141, pp.1742~1759 (2020)
29. Paquette M, "Predicting cardiovascular disease in familial hypercholesterolemia", Curr Opin Lipidol, 29, pp.299~306 (2018)
30. Raal FJ, "Familial hypercholesterolemia treatments : guidelines and new therapies", Atherosclerosis, 277, pp.483~492 (2018)
31. Samuel R, "Prevalence of familial hypercholesterolaemia in acute coronary syndrome patients in a large regional coronary care unit", Heart Lung Circ, 30, pp.730~733 (2021)
32. Kheiri B, "Familial hypercholesterolemia related admission for acute coronary syndrome in the United States : incidence, predictors, and outcomes", J Clin Lipidol, 15, pp.460~465 (2021)
33. Takasaki A, "Prevalence and prognosis of familial hypercholesterolemia in patients with acute coronary syndrome in Mie Prefecture, Japan-report from Mie ACS registry", Circ J, 85, pp.9~18 (2020)
34. Shin DG, "Clinical features of familial hypercholesterolemia in Korea : predictors of pathogenic mutations and coronary artery disease-A study supported by the Korean Society of Lipidology and Atherosclerosis", Atherosclerosis, 243, pp.53~58 (2015)
35. Pirillo A, "Spectrum of mutations in Italian patients with familial hypercholesterolemia : new results from the LIPIGEN study", Atheroscler Suppl, 29, pp.17~24 (2017)
36. Tada H, "A catalog of the pathogenic mutations of LDL receptor gene in Japanese familial hypercholesterolemia", J Clin Lipidol, 14, pp.346~351 (2020)
37. Taylor A, "Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project", Clin Genet, 77, pp.572~580 (2010)
38. Reeskamp LF, "Next-generation sequencing to confirm clinical familial hypercholesterolemia", Eur J Prev Cardiol, 28, pp.875~883 (2021)
39. Stitziel NO, "Exome sequencing in suspected monogenic dyslipidemias", Circ Cardiovasc Genet, 8, pp.343~350 (2015)
40. Khera AV, "Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia", J Am Coll Cardiol, 67, pp.2578~2589 (2016)
41. Tada H, "Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia", Eur Heart J, 38, pp.1573~1579 (2017)
42. Austin MA, "Genetic causes of monogenic heterozygous familial hypercholesterolemia : a HuGE prevalence review", Am J Epidemiol, 160, pp.407~420 (2004)
43. Scientific Steering Committee on behalf of the Simon Broome Register Group, "Risk of fatal coronary heart disease in familial hypercholesterolaemia", BMJ, 303, pp.893~896 (1991)
44. Harada-Shiba M, "Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017", J Atheroscler Thromb, 25, pp.751~770 (2018)
45. Santos RD, "Defining severe familial hypercholesterolaemia and the implications for clinical management : a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel", Lancet Diabetes Endocrinol, 4, pp.850~861 (2016)
46. Tada H, "Clinical diagnostic criteria of familial hypercholesterolemia-A comparison of the Japan Atherosclerosis Society and Dutch lipid clinic network criteria", Circ J, 85, pp.891~897 (2021)
47. Tada H, "A reassessment of the Japanese clinical diagnostic criteria of familial hypercholesterolemia in a hospital-based cohort using comprehensive genetic analysis", Pract Lab Med, 22, pp.e00180~ (2020)
48. Tada H, "Achilles tendon thickness assessed by X-ray predicting a pathogenic mutation in familial hypercholesterolemia gene", J Atheroscler Thromb (2021)
49. Tada H, "Effect of cumulative exposure to low-density lipoprotein-cholesterol on cardiovascular events in patients with familial hypercholesterolemia", Circ J, 85, pp.2073~2078 (2021)
50. de Gennes JL, "Direct fetal blood examination for prenatal diagnosis of homozygous familial hypercholesterolemia", Arteriosclerosis, 5, pp.440~442 (1985)
51. Daida H, "The goal of achieving atherosclerotic plaque regression with lipid-lowering therapy : insights from IVUS trials", J Atheroscler Thromb, 26, pp.592~600 (2019)
52. Maurovich-Horvat P, "Comprehensive plaque assessment by coronary CT angiography", Nat Rev Cardiol, 11, pp.390~402 (2014)
53. Pérez de Isla L, "Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia : a computed tomographic angiography study", Atherosclerosis, 317, pp.52~58 (2021)
54. Okada H, "Aortic root calcification score as an independent factor for predicting major adverse cardiac events in familial hypercholesterolemia", J Atheroscler Thromb, 25, pp.634~642 (2018)
55. Miname MH, "Vascular age derived from coronary artery calcium score on the risk stratification of individuals with heterozygous familial hypercholesterolaemia", Eur Heart J Cardiovasc Imaging, 21, pp.251~257 (2020)
56. Gallo A, "The added value of coronary calcium score in predicting cardiovascular events in familial hypercholesterolemia", JACC Cardiovasc Imaging, 14, pp.2414~2424 (2021)
57. Liu Z, "Percutaneous coronary intervention for a Chinese familial hypercholesterolemia homozygous under the guidance of optical coherence tomography", Atheroscler Suppl, 36, pp.19~23 (2019)
58. Katamine M, "Familial hypercholesterolemia and vulnerability of coronary plaque in patients with coronary artery disease", Pract Lab Med, 24, pp.e00202~ (2021)
59. Tada H, "Assessments of carotid artery plaque burden in patients with familial hypercholesterolemia", Am J Cardiol, 120, pp.1955~1960 (2017)
60. Tada H, "Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography", Am J Cardiol, 115, pp.724~729 (2015)
61. Tada H, "Assessment of arterial stiffness in patients with familial hypercholesterolemia", J Clin Lipidol, 12, pp.397~402 (2018)
62. Tada H, "Remnant-like particles and coronary artery disease in familial hypercholesterolemia", Clin Chim Acta, 482, pp.120~123 (2018)
63. Gidding SS, "The agenda for familial hypercholesterolemia : a scientific statement from the American Heart Association", Circulation, 132, pp.2167~2192 (2015)
64. Li S, "Significance of lipoprotein(a)levels in familial hypercholesterolemia and coronary artery disease", Atherosclerosis, 260, pp.67~74 (2017)
65. Vuorio A, "Familial hypercholesterolemia and elevated lipoprotein(a) : double heritable risk and new therapeutic opportunities", J Intern Med, 287, pp.2~18 (2020)
66. Tada H, "Lipoprotein(a)in familial hypercholesterolemia with proprotein convertase subtilisin", kexin Type 9(PCSK9)gain-of-function mutations, 2016, pp.80, 512~518
67. Tada H, "Familial hypercholesterolemia : a narrative review on diagnosis and management strategies for children and adolescents", Vasc Health Risk Manag, 17, pp.59~67 (2021)
68. Luirink IK, "20-year follow-up of statins in children with familial hypercholesterolemia", N Engl J Med, 381, pp.1547~1556 (2019)
69. Tada H, "Low-density lipoprotein cholesterol level cannot be too low : considerations from clinical trials, human genetics, and biology", J Atheroscler Thromb, 27, pp.489~498 (2020)
70. Lozano P, "Lipid screening in childhood and adolescence for detection of familial hypercholesterolemia : Evidence report and systematic review for the US Preventive Services Task Force", JAMA, 316, pp.645~655 (2016)
71. Groselj U, "Universal screening for familial hypercholesterolemia in children : the Slovenian model and literature review", Atherosclerosis, 277, pp.383~391 (2018)
72. Wiegman A, "Familial hypercholesterolaemia in children and adolescents : gaining decades of life by optimizing detection and treatment", Eur Heart J, 36, pp.2425~2437 (2015)
73. Tada H, "Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events", J Clin Lipidol, 15, pp.358~365 (2021)
74. Nordestgaard BG, "Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population : guidance for clinicians to prevent coronary heart disease : consensus statement of the European Atherosclerosis Society", Eur Heart J, 34, pp.3478~3490 (2013)
75. Brautbar A, "Genetics of familial hypercholesterolemia", Curr Atheroscler Rep, 17, pp.491~ (2015)
76. Kim H, "GENetic characteristics and REsponse to lipid-lowering therapy in familial hypercholesterolemia : GENRE-FH study", Sci Rep, 10, pp.19336~ (2020)
77. Lee SH, "Characteristics and vascular complications of familial hypercholesterolemia in Korea", J Atheroscler Thromb, 23, pp.532~538 (2016)
78. Santos PC, "Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment", Pharmacogenomics, 16, pp.1743~1750 (2015)
79. Talmud PJ, "Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia : a case-control study", Lancet, 381, pp.1293~1301 (2013)
80. Kwon M, "Evaluation of polygenic cause in Korean patients with familial hypercholesterolemia-A study supported by Korean Society of Lipidology and Atherosclerosis", Atherosclerosis, 242, pp.8~12 (2015)
81. Wang J, "Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically", Arterioscler Thromb Vasc Biol, 36, pp.2439~2445 (2016)
82. Mariano C, "The familial hypercholesterolaemia phenotype : monogenic familial hypercholesterolaemia, polygenic hypercholesterolaemia and other causes", Clin Genet, 97, pp.457~466 (2020)
83. Tada H, "Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease", J Clin Lipidol, 12, pp.1436~1444 (2018)
84. Tada H, "Diagnosis and management of sitosterolemia 2021", J Atheroscler Thromb, 28, pp.791~801 (2021)
85. Nomura A, "Heterozygous ABCG5 gene deficiency and risk of coronary artery disease", Circ Genom Precis Med, 13, pp.417~423 (2020)
86. Tada H, "Post-prandial remnant lipoprotein metabolism in autosomal recessive hypercholesterolaemia", Eur J Clin Invest, 42, pp.1094~1099 (2012)
87. Tada H, "Autosomal recessive hypercholesterolemia : a mild phenotype of familial hypercholesterolemia : insight from the kinetic study using stable isotope and animal studies", J Atheroscler Thromb, 22, pp.1~9 (2015)
88. Karczewski KJ, "The mutational constraint spectrum quantified from variation in 141, 456 humans", Nature, 581, pp.434~443 (2020)
89. Kawamura R, "Acute myocardial infarction in a 25-year-old woman with sitosterolemia", J Clin Lipidol, 12, pp.246~249 (2018)
90. Tanaka H, "Sitosterolemia exhibiting severe hypercholesterolemia with tendon xanthomas due to compound heterozygous ABCG5 gene mutations treated with ezetimibe and alirocumab", Intern Med, 59, pp.3033~3037 (2020)
91. Yamada Y, "Premature acute myocardial infarction in a young patient with sitosterolemia", CJC Open, 3, pp.1085~1088 (2021)
92. Tada H, "Sitosterolemia, hypercholesterolemia, and coronary artery disease", J Atheroscler Thromb, 25, pp.783~789 (2018)
93. Tada H, "Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history", Eur Heart J, 37, pp.561~567 (2016)
94. Fahed AC, "Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions", Nat Commun, 11, pp.3635~ (2020)

관련 논문AI추천